文献速递胸部肿瘤

SARS-CoV-2 疫情对初诊肺癌患者管理与预后的影响:一项回顾性多中心真实世界队列研究

Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre real-life cohort study.
PubMed 文献 · Eur J Cancer · 2022-06-27

首次封锁期间新诊断率下降 32%,肿瘤分期、治疗分布及多学科肿瘤委员会相关延迟未变;接受手术或全身抗肿瘤治疗者 6 个月总生存率无显著差异,仅最佳支持治疗者 6 个月总生存率 2020 年低于 2018-2019 年。

要点

  • 首次封锁期间新诊断肺癌病例数较 2018-2019 年下降 32%。
  • 初诊肿瘤分期、治疗类别分布及多学科肿瘤委员会相关延迟未见变化。
  • 接受手术或全身抗肿瘤治疗者 6 个月总生存率在两个时段无显著差异。

核心结论

  • SARS-CoV-2 疫情对巴黎大学医院接受积极抗肿瘤治疗的初诊肺癌患者 6 个月总生存率未产生有害影响。

研究设计与样本

  • 比较 2018-2019 年与 2020 年初诊肺癌病例的新诊断率、初始肿瘤分期、多学科肿瘤委员会至抗肿瘤治疗启动延迟及 6 个月总生存率。

主要发现

  • 共 6240 例肺癌患者,2179 例(35%)接受肿瘤切除术,2069 例(33%)接受全身抗肿瘤治疗,775 例(12%)接受最佳支持治疗,1217 例(20%)未接受任何治疗。
  • 首次封锁期间新诊断率较 2018-2019 年下降 32%。
  • 2018-2019 年诊断并接受肿瘤切除术者 6 个月总生存率为 98%,2020 年诊断者为 97%(HR=1.2;95%CI:0.7-2.0)。
  • 2018-2019 年诊断并接受全身抗肿瘤治疗者 6 个月总生存率为 78%,2020 年诊断者为 79%(HR=1.0;95%CI:0.8-1.2)。
  • 2018-2019 年诊断并接受最佳支持治疗者 6 个月总生存率为 20%,2020 年诊断者为 13%(HR=1.3;95%CI:1.1-1.6)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The SARS-CoV-2 pandemic has impacted the care of cancer patients. This study sought to assess the pandemic's impact on the clinical presentations and outcomes of newly referred patients with lung cancer from the Greater Paris area. METHODS: We retrospectively retrieved the electronic health records and administrative data of 11.4 million patients pertaining to Greater Paris University Hospital (AP-HP). We compared indicators for the 2018-2019 period to those of 2020 in regard to newly referred lung cancer cases. We assessed the initial tumour stage, the delay between the first multidisciplinary tumour board (MTB) and anticancer treatment initiation, and 6-month overall survival (OS) rates depending on the anticancer treatment, including surgery, palliative systemic treatment, and best supportive care (BSC). RESULT: Among 6240 patients with lung cancer, 2179 (35%) underwent tumour resection, 2069 (33%) systemic anticancer therapy, 775 (12%) BSC, whereas 1217 (20%) did not receive any treatment. During the first lockdown, the rate of new diagnoses decreased by 32% compared with that recorded in 2018-2019. Initial tumour stage, repartition of patients among treatment categories, and MTB-related delays remained unchanged. The 6-month OS rates of patients diagnosed in 2018-2019 who underwent tumour resection were 98% versus 97% (HR = 1.2; 95% CI: 0.7-2.0) for those diagnosed in 2020; the respective rates for patients who underwent systemic anticancer therapy were 78% versus 79% (HR = 1.0; 95% CI: 0.8-1.2); these rates were 20% versus 13% (HR = 1.3; 95% CI: 1.1-1.6) for those who received BSC. COVID-19 was associated with poorer OS rates (HR = 2.1; 95% CI: 1.6-3.0) for patients who received systemic anticancer therapy. CONCLUSIONS: The SARS-CoV-2 pandemic has not exerted any deleterious impact on 6-month OS of new lung cancer patients that underwent active anticancer therapy in Greater Paris University hospitals.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Priou S, Lamé G, Zalcman G, et al. Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre real-life cohort study. Eur J Cancer. 2022. PMID: 35843177. doi:10.1016/j.ejca.2022.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。